Tryptamine Therapeutics (AU:TYP) has released an update.
Claim 30% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Tryptamine Therapeutics, a clinical-stage biotech company, has altered its reporting status in Canada to a ‘designated foreign issuer’ while continuing to meet Australian regulatory requirements. The company has successfully completed Phase 2a clinical trials for binge eating disorder and fibromyalgia and is advancing trials on a proprietary IV-infused psilocin treatment designed to improve patient outcomes.
For further insights into AU:TYP stock, check out TipRanks’ Stock Analysis page.